
|Articles|November 15, 2013
- NSCLC (Issue 1)
- Volume 1
- Issue 1
The Treatment of Lung Cancer Subgroups
Author(s)Chandra P. Belani, MD
Chandra P. Belani, MD, from the Penn State Hershey Cancer Institute, discusses the treatment of subgroups of patients with lung cancer.
Advertisement
Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses the treatment of subgroups of patients with lung cancer.
Read more abouttreating squamous and nonsquamous diseas
Articles in this issue
about 12 years ago
Molecular Targeted Agents for Stage III NSCLCabout 12 years ago
Molecular Targets in Non-Small Cell Lung Cancerabout 12 years ago
Multidisciplinary Perspectives: Molecular Testing in NSCLCabout 12 years ago
World Conference on Lung Cancer 2013 Highlightsabout 12 years ago
Guidelines for Molecular Testing in Lung Cancerabout 12 years ago
Treating Squamous vs Nonsquamous DiseaseAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















